Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer

Head and neck squamous cell carcinomas are rising in incidence worldwide, and despite the advent of improved surgical and radiation techniques, a substantial proportion of patients have disease recurrence, where systemic therapies are the mainstay of management. Recent advances in systemic therapy include the development of epidermal growth factor receptor- and programmed death 1-targeting drugs, which have produced incremental improvements in disease outcomes. However, for most patients, responses to treatment remain elusive because of primary or acquired resistance. Novel drugs and rational drug combinations need to be tested based on biomarker identification and preclinical science that will ultimately advance outcomes for our patients. This review focuses on efforts untaken for epidermal growth factor receptor targeting in head and neck squamous cell carcinoma to date.

Automated summary

Head and neck squamous cell carcinomas are increasing in incidence, and systemic therapies are the main treatment for disease recurrence. However, responses to treatment are often limited due to resistance. Novel drugs and drug combinations need to be developed based on biomarkers and preclinical research to improve patient outcomes.